Showing results (611-620 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|July 11, 2007
Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesisThorsten Hagemann, Stephen C Robinson, Richard G Thompson, et al.
Molecular Cancer Therapeutics|June 21, 2008
Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cellsMichela Muscolini, Roberta Cianfrocca, Angela Sajeva, et al.
Molecular Cancer Therapeutics|June 21, 2008
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signalingRentian Feng, Huihui Ma, Christian A Hassig, et al.
Molecular Cancer Therapeutics|June 21, 2008
Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell linesMedhi Wangpaichitr, Niramol Savaraj, Johnathan Maher, et al.
Molecular Cancer Therapeutics|June 21, 2008
Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxinMitomu Kioi, Saraswathy Seetharam, Raj K Puri
Molecular Cancer Therapeutics|June 21, 2008
DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasisShulamit Batya Wallach-Dayan, Ariel M Rubinstein, Carla Hand, et al.
Molecular Cancer Therapeutics|June 21, 2008
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancerShadan Ali, Sanjeev Banerjee, Aamir Ahmad, et al.
Molecular Cancer Therapeutics|September 19, 2007
Characterization of novel inhibitors of histone acetyltransferasesElena D Eliseeva, Vassil Valkov, Manfred Jung, et al.
Molecular Cancer Therapeutics|September 19, 2007
Improved low molecular weight Myc-Max inhibitorsHuabo Wang, Dalia I Hammoudeh, Ariele Viacava Follis, et al.
Molecular Cancer Therapeutics|September 19, 2007
Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanismsBolan Yu, Birgit M Dietz, Tareisha Dunlap, et al.
Pageof 599